TrialFrontiers in immunology2026

A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer.

Jie Lan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.